A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2029-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability,
immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with
lenalidomide and/or rituximab in patients with indolent NHL